CBA Florida, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2012-10-04: Form 8-K; Period of report 2012-09-28; Description 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 8.01 Other Events; Details 1.01.
- 2012-09-27: Form 8-K; Period of report 2012-09-25; Description 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Details 5.03.
- 2012-07-06: Form 8-K; Period of report 2012-06-29; Description 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; Details 1.01.
- 2012-06-25: Form 8-K; Period of report 2012-06-22; Description 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 8.01 Other Events; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2012-10-04 | 8-K | 2012-09-28 | 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 8.01 Other Events | 1.01 Cord Blood America, Inc. (the "Company") entered into an Agreement on waiver of claims, Agreement on Purchase and Assignment of Claims, and Share Purchase Agreement (the “Agreement”) with Medivision Betriebsgesellschaft mbH (“Medivision”), along with additional parties as set forth in the Agreement, pursuant to which the Company sold its ownership stake in stellacure GmbH, a German company (“stellacure”) to Medivision, and whereby the transaction closed on September 28, 2012. 2.01 All of Item 1.01 above is incorporated herein. 8.01 On October 4, 2012, the Company issued a press release regarding the transaction detailed in this report. | cbai_8k.htm |
| 2012-09-27 | 8-K | 2012-09-25 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 On September 25, 2012, Cord Blood America, Inc.’s (the “Company”) Amended and Restated Articles of Incorporation were amended to increase authorized capital stock to 895,000,000 shares, consisting of 5,000,000 shares of Preferred stock, par value $0.0001, and 890,000,000 shares of Common Stock, par value $0.0001. | cbai_8k.htm |
| 2012-07-06 | 8-K | 2012-06-29 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities | 1.01 In a transaction that closed on June 29, 2012, Cord Blood America, Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with Tonaquint, Inc. a Utah corporation (the "Investor") whereby the Company issued and sold, and the Investor purchased a Secured Convertible Promissory Note of the Company in the principal amount of $1,252,000 (the "Company Note"). 3.02 The information called for by this item is contained in Item 1.01, which is incorporated herein by reference. | cbai_8k.htm |
| 2012-06-25 | 8-K | 2012-06-22 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 8.01 Other Events | 1.01 As of June 22, 2012, Cord Blood America, Inc. (the "Company") entered into an Agreement with SEBASTIÁN NICOLÁS NEUSPILLER, DIEGO ESTEBAN RISSOLA, JORGE ALEJANDRO JURADO, MAURO LEONARDO BRUNO, and ALEJANDRO JORGE RICO DOUGLAS (the "Sellers"), from whom the Company purchased its majority ownership interest in Biocordcell Argentina S.A., an Argentine corporation (“BioCells”) in 2010. 8.01 On June 25, 2012, the Company issued a press release regarding the transaction detailed in this report. | cbai_8k.htm |
| 2012-05-25 | 8-K | 2012-05-25 | 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review | 4.02 On May 11, 2012, the Company concluded, and the Audit Committee of the Board of Directors approved, that the previously filed unaudited consolidated financial statements contained in the Company’s Quarterly Report on Form 10-Q for the three months and nine months ended September 30, 2011, originally filed with the Securities and Exchange Commission on November 14, 2011 (the “Original Filing”), should no longer be relied upon for the reasons set forth herein. | cbai_8k.htm |
| 2012-05-15 | 8-K | 2012-05-14 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 Effective as of May 14, 2012, Mathew Schissler resigned from his positions as Chairman, Chief Executive Officer, Secretary, and as a Director of Cord Blood America, Inc. (the “Company”). 7.01 Effective May 14, 2012, the Company and Pyrenees Consulting, LLC (“Pyrenees”) terminated their arrangement, and Pyrenees no longer provides services for the Company. | cbai_8k.htm |